AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03108716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hamate hook removal
Description: The patients were assigned to treat with hamate hook removal.
Study NCT03108716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microscrew internal fixation
Description: The patients were assigned to treat with microscrew internal fixation after open reduction.
Study NCT03108716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short-arm tube-type plaster fixation
Description: The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
Study NCT00291720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
Study NCT00291720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT02286817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1
Description: Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
Study NCT00358813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant
Description: Casopitant oral tablets will be available with a dose of 50 milligrams.
Study NCT02446587 — intervention group
Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
Study NCT04060615 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: percutaneous coronary intervention
Description: PCI of the chronic total occlusion of the coronary artery
Study NCT02236169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide HFA-134a inhalation aerosol
Study NCT02236169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent CFC inhalation aerosol
Study NCT02667184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low FODMAP Oral Nutrition Supplement
Study NCT01511484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information-only
Description: Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions
Study NCT01511484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic appearance intervention
Description: Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour.
Study NCT01511484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised appearance intervention
Description: Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
Study NCT02639351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R
Description: Intramuscular (IM) vaccination of 1 dose of 0.5 mL
Study NCT02639351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MenC-CRM adjuavnted with 25 ug of LHD153R
Description: IM vaccination of 1 dose of 0.5 mL
Study NCT04906863 — intervention group
Intervention type: GENETIC
Intervention: Blood draw
Description: Blood draw for identification of genetic variants associated with the development of memory problems
Study NCT04906863 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive testing
Description: Brief memory test
Study NCT00736515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide MR and Insulin Glargine Injection
Description: Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
Study NCT00736515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biosynthetic Human Insulin Injection
Description: Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
Study NCT01797770 — intervention group
Intervention type: DRUG
Intervention: polyethylene glycol
Description: mechanical bowel preparation with polyethylene glycol one day prior to surgery
Study NCT01797770 — intervention group
Intervention type: OTHER
Intervention: No Preparation
Description: No laxatives or bowel preparation
Study NCT01325792 — intervention group
Intervention type: DEVICE
Intervention: GORE® BIO-A® Tissue Reinforcement
Description: Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
Study NCT02336126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biopsychological intervention
Study NCT01661582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT/PET Myocardial Perfusion Imaging using O-15 water
Study NCT01661582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CT/PET Myocardial Perfusion Imaging using O-15 water
Study NCT01661582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary blood flow measured by doppler echocardiography
Study NCT01661582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coronary blood flow measured by doppler echocardiography
Study NCT03174002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
Study NCT03174002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
Study NCT04083729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Mitral Commissurotomy
Description: Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
Study NCT01456767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.
Study NCT01456767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.
Study NCT01204723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Aprepitant
Description: Placebo Aprepitant 0 mg once daily for 5 days
Study NCT01204723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Aprepitant
Description: Active Aprepitant 160 mg once daily for 5 days
Study NCT00522132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: intravenous application
Study NCT00522132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: intravenous application
Study NCT03900689 — intervention group
Intervention type: OTHER
Intervention: Part 1 Survey Group
Description: At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
Study NCT03900689 — intervention group
Intervention type: OTHER
Intervention: Part 2 Focus Group
Description: If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
Study NCT00527891 — intervention group
Intervention type: PROCEDURE
Intervention: Signa Excite 3.0 T MRI Scan
Description: Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
Study NCT03841084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit
Study NCT04185597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFP Intervention: Delivered by Community Farmers
Description: Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
Study NCT04185597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFP Intervention: Delivered by agricultural Retailers
Description: HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
Study NCT04185597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Current Standard of Practice
Study NCT03279393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluorodeoxyglucose (FDG)-PET/MRI
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
Study NCT03279393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorodeoxyglucose (FDG)-PET/MRI
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
Study NCT02639351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
Description: IM vaccination of 1 dose of 0.5 mL
Study NCT02639351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R
Description: IM vaccination of 1 dose of 0.5 mL
Study NCT02639351 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)
Description: IM vaccination of 1 dose of 0.5 mL
Study NCT00601952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
Study NCT00601952 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition (ACC)
Description: The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
Study NCT03018548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
Study NCT03690154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FN-1501
Description: Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
Study NCT00619008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum low carbohydrate diet
Description: 6 week ad libitum low carbohydrate diet
Study NCT00619008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum High Complex Carbohydrate Diet
Description: 6 week ad libitum high complex carbohydrate diet
Study NCT00619008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-restricted high complex carbohydrate diet
Description: 6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
Study NCT03705481 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Remote treatment of PCI.
Description: To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
Study NCT01727960 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education and posture correction
Description: a lecture concerning the fine posture for health and exercises
Study NCT00348140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 2mg
Description: Rosiglitazone Extended Release 2mg OD
Study NCT00348140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 8mg
Description: Rosiglitazone Extended Release 8mg OD
Study NCT00348140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00516919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenical + behavioral intervention
Description: 120 mg TID; Behavioral weight loss in Spanish
Study NCT00516919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention + placebo
Description: Behavioral weight loss treatment in Spanish Placebo TID
Study NCT01872455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 rich diet
Description: This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
Study NCT01872455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: Usual diet of the patients
Study NCT04686422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetric PowerFill
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
Study NCT00844493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli strain H10407 and buffer
Description: 7 or 8 logs of the bacteria with bicarbonate buffer
Study NCT00844493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli strain H10407 and buffer
Description: Bacteria in a dose of 8 logs with CeraVacx buffer
Study NCT00844493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli strain H10407 and buffer
Description: Bacteria in a dose of 7 logs and CeraVacx buffer
Study NCT00844493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli H10407 and buffer
Description: Bacteria in a dose of 8 logs with bicarbonate buffer
Study NCT01997151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Pregnancy: Step by Step
Study NCT01804231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 18F-FCH PET/MRI imaging
Description: Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
Study NCT04906863 — intervention group
Intervention type: OTHER
Intervention: Medical questionnaire
Description: Collection of medical history
Study NCT01508455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT01508455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01508455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT01508455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study NCT04095455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectoral nerves block group
Description: ultrasound guided block of nerve supply of surgical site
Study NCT04095455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus magnesium group
Description: Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
Study NCT04095455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
Study NCT01656525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: 75 mg subcutaneous doses every 4 weeks for 24 weeks
Study NCT01656525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: 105 mg subcutaneous doses every 4 weeks for 24 weeks
Study NCT01656525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: 225 mg subcutaneous doses every 4 weeks for 24 weeks
Study NCT01656525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous doses every 4 weeks for 24 weeks
Study NCT03068715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS-DLPFC
Description: Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator.
Study NCT03068715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.